Anixa Biosciences (ANIX) - Rentabilitas dodolan reged

Anixa Biosciences is engaged in a patent battle within the high-risk vaccine race, leveraging streamlined component supply chains. On GURU.Markets, the gross margin reflects profit dynamics net of costs, with the indicator standing at 0.00. Proprietary developments in the treatment of female cancers create barriers to entry, transforming future products into high-yield assets.
Rincian metrik keuangan lan pasar anixa.com (ANIX)

Automation of breast cancer drug synthesis at Anixa Biosciences (ANIX) reduces costs, yet medical oversight expenses in clinics directly impact the cost of goods sold. The gross margin as a percentage of revenue reflects the efficiency of this balance, measuring the percentage of funds remaining after covering direct production costs, which allows investors to assess the fundamental profitability of the business through historical peaks and troughs.